- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05575037
Mechanismy přínosu inhibice IL4RA u respiračního onemocnění exacerbovaného aspirinem (MARINER)
Mechanismy přínosu inhibice IL4RA u respiračního onemocnění exacerbovaného aspirinem: MARINER
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Brigham and Women's Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Key Inclusion Criteria:
-
History of AERD, defined as meeting the diagnostic triad with:
- History of physician-diagnosed asthma and
- History of physician-diagnosed nasal polyposis and
- History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
-
Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.
-
Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.
-
Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).
-
Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.
-
No current smoking (not more than one instance of smoking in the last 3 months).
-
For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.
Key Exclusion Criteria:
- Use of investigational drugs within 12 weeks of Screening.
- Use of any biologic agent within 4 months prior to Screening.
- Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
- History of any sinonasal surgery within 4 months prior to Screening
- Current use of zileuton
- Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
- Pregnant, nursing, or planning to become pregnant
Note: Other inclusion and exclusion criteria apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Dupilumab
Subjects will receive dupilumab (300mg every-other-week for 8 weeks). |
8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Nasal Fluid Levels of LTE4
Časové okno: At Week 8 (Visit 3)
|
The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden. |
At Week 8 (Visit 3)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Nasal Fluid Levels of Albumin
Časové okno: At Week 8 (Visit 3)
|
The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity. |
At Week 8 (Visit 3)
|
|
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Časové okno: At Week 8 (Visit 3)
|
Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
At Week 8 (Visit 3)
|
|
Rhinoscopic Total Polyp Score (TPS)
Časové okno: At Week 8 (Visit 3)
|
The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
At Week 8 (Visit 3)
|
|
Peak Nasal Inspiratory Flow (PNIF)
Časové okno: At Week 8 (Visit 3)
|
Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
At Week 8 (Visit 3)
|
|
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Časové okno: At Week 8 (Visit 3)
|
Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
At Week 8 (Visit 3)
|
|
Lung Function - Forced Expiratory Volume 1 (FEV1)
Časové okno: At Week 8 (Visit 3)
|
Patients' lung function will be assessed at week 8 with an FEV1. |
At Week 8 (Visit 3)
|
|
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Časové okno: At Week 8 (Visit 3)
|
Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
At Week 8 (Visit 3)
|
|
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Časové okno: At Week 8 (Visit 3)
|
Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation. |
At Week 8 (Visit 3)
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified) |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Rhinoscopic Total Polyp Score (TPS)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Peak Nasal Inspiratory Flow (PNIF)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control). |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Eicosanoids
Časové okno: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels. |
weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Nasal Fluid Levels of Albumin
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Urinary Levels of Eicosanoids
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Serum Tryptase
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in IgE Levels
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
|
Change in Eosinophilic Cationic Protein (ECP)
Časové okno: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP. |
2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Tanya M Laidlaw, MD, Brigham and Women's Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Patologické stavy, anatomické
- Onemocnění imunitního systému
- Nemoci dýchacích cest
- Bronchiální onemocnění
- Respirační přecitlivělost
- Přecitlivělost, okamžitá
- Přecitlivělost
- Chemicky indukované poruchy
- Nemoci nosu
- Otorinolaryngologická onemocnění
- Vedlejší účinky a nežádoucí účinky související s léky
- Polypy
- Přecitlivělost na léky
- Astma
- Patologické stavy, příznaky a symptomy
- Nosní polypy
- Astma vyvolané aspirinem
- dupilumab
Další identifikační čísla studie
- 2022P002407
- U19AI095219 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .